Joop E. Arends , Faydra I. Lieveld , Lauke L. Boeijen , Clara T.M.M. de Kanter , Karel J. van Erpecum , Dominique Salmon , Andy I.M. Hoepelman , Tarik Asselah , Andrew Ustianowski
{"title":"Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?","authors":"Joop E. Arends , Faydra I. Lieveld , Lauke L. Boeijen , Clara T.M.M. de Kanter , Karel J. van Erpecum , Dominique Salmon , Andy I.M. Hoepelman , Tarik Asselah , Andrew Ustianowski","doi":"10.1016/j.jhep.2015.06.034","DOIUrl":null,"url":null,"abstract":"<div><p><span>Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV<span> therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted </span></span>drug resistance.</p></div>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"63 5","pages":"Pages 1254-1262"},"PeriodicalIF":26.8000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jhep.2015.06.034","citationCount":"53","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168827815004626","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 53
Abstract
Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.
期刊介绍：
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
